Correlation Between Mineralys Therapeutics, and Arcellx

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Arcellx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Arcellx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Arcellx, you can compare the effects of market volatilities on Mineralys Therapeutics, and Arcellx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Arcellx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Arcellx.

Diversification Opportunities for Mineralys Therapeutics, and Arcellx

0.44
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Mineralys and Arcellx is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Arcellx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Arcellx and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Arcellx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Arcellx has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Arcellx go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Arcellx

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 1.05 times more return on investment than Arcellx. However, Mineralys Therapeutics, is 1.05 times more volatile than Arcellx. It trades about -0.02 of its potential returns per unit of risk. Arcellx is currently generating about -0.15 per unit of risk. If you would invest  1,311  in Mineralys Therapeutics, Common on September 28, 2024 and sell it today you would lose (43.50) from holding Mineralys Therapeutics, Common or give up 3.32% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Mineralys Therapeutics, Common  vs.  Arcellx

 Performance 
       Timeline  
Mineralys Therapeutics, 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Arcellx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Arcellx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong essential indicators, Arcellx is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Mineralys Therapeutics, and Arcellx Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mineralys Therapeutics, and Arcellx

The main advantage of trading using opposite Mineralys Therapeutics, and Arcellx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Arcellx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcellx will offset losses from the drop in Arcellx's long position.
The idea behind Mineralys Therapeutics, Common and Arcellx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets